Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Pioneering Treatment | Immunovant's novel anti-FcRn therapy shows promise for autoimmune diseases, particularly Graves' disease, with potential for best-in-class efficacy |
Market Potential | Explore the substantial opportunity in Graves' disease, with an estimated 20,000 high-need patients diagnosed annually in the US |
Analyst Optimism | Price targets range from $36 to $58, suggesting significant upside potential despite recent stock decline. Average target stands at $57 |
Strategic Expansion | Delve into Immunovant's ambitious plan to target 10 indications by 2026, diversifying risk and expanding market potential |
Metrics to compare | IMVT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMVTPeersSector | |
---|---|---|---|---|
P/E Ratio | −10.8x | −1.9x | −0.6x | |
PEG Ratio | 0.83 | −0.05 | 0.00 | |
Price/Book | 7.8x | 0.7x | 2.6x | |
Price / LTM Sales | - | 2.8x | 3.1x | |
Upside (Analyst Target) | 112.2% | 81.3% | 51.5% | |
Fair Value Upside | Unlock | 23.5% | 8.4% | Unlock |